Cobalis Corp. PreHistin(TM) to Be Granted European Union Patent
November 02 2005 - 8:30AM
PR Newswire (US)
European Patent Office Allows New Patent for PreHistin(TM) --
'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov.
2 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN
BOARD: CLSC) , announced today that following an oral presentation
to the European Patent Office in Munich, Germany, a panel of three
patent examiners accepted Cobalis' claims for PreHistin(TM) as a
unique treatment for allergies and other atopic diseases. The
patent "Cyanocobalamin Treatment in Allergic Disease", European
Patent EP1128835, grants Cobalis extensive patent protection paving
the way for marketing PreHistin(TM) throughout the European Union
where an estimated 80 million people suffer from seasonal and
perennial allergies, as well as a host of other atopic diseases
such as atopic asthma, atopic migraine and dermatitis.
PreHistin(TM) is a sublingual lozenge containing an
allergy-opposing amount of cyanocobalamin that is absorbed through
the buccal membrane, allowing direct introduction of the active
ingredient into the bloodstream. In this manner, PreHistin(TM) is
distinguished from orally-ingested cyanocobalamin which first
passes through the digestive tract before the active ingredient is
systemically available. As a sublingual lozenge, PreHistin(TM) has
a significantly higher bioavailability of cyanocobalamin than
orally-ingested tablets or capsules. The European patent is a
strong extension of Cobalis' already-granted patent portfolio
consisting of two patents in the US, and one in Australia. In
addition, Cobalis' PreHistin(TM) has patents pending in several
other major pharmaceutical markets including Mexico, Canada and
Japan. Said Ernie Armstrong, Chief Scientific Officer for Cobalis:
"PreHistin(TM) is truly a novel approach to treating allergic
disease. PreHistin(TM) is a safe, non-drowsy and highly effective
way to mitigate the onset and severity of allergy symptoms. Its
mechanism of action, whereby PreHistin(TM) lowers IgE levels to
reduce the release of symptom-causing histamine and other allergic
inflammatory mediators into the body, is truly unique. In allowing
this patent for the European Union, the European Patent Office has
recognized the unique and novel approach of this breakthrough
treatment, paving the way for Cobalis to market PreHistin(TM) to
the estimated 80+ million allergy sufferers throughout Europe as an
alternative to the currently available antihistamines, which are
typically sedating and may have numerous unpleasant side effects.
In contrast, PreHistin(TM) is completely non-sedating and there
have been no known common side effects reported in our clinical
studies." Said Marty Marion, Cobalis' Chief Marketing Officer: "The
European Union patent adds an important dimension to our
international franchise for PreHistin(TM) and further demonstrates
the uniqueness of this alternative treatment for allergic and
atopic disease. As we continue to develop clinical applications for
PreHistin(TM) to treat allergies, as well as atopic asthma, atopic
migraine and other diseases triggered by IgE (Immunoglobulin E)
overproduction, our expanding base of international patents adds
tremendous value to our growing product portfolio and to our
Company. It is estimated that in many countries atopic disease
affects as much as 75% of the population. PreHistin(TM) will
provide consumers with the safest, most effective and least costly
approach to controlling and treating allergic disease. Patents,
such as the European Union patent, allow us a strong protective
playing field in which to bring our product to market." Following
translation and publication of the European Union patent
application into French, German and several other EU languages,
Cobalis expects the European Patent Office to publish the official
allowance of the patent early in 2006. Cobalis intends to commence
marketing PreHistin(TM) in Europe in 2006 following formal
publication of the issued EU patent. ABOUT COBALIS CORP. -
PREHISTIN(TM) Headquartered in Irvine, California, Cobalis Corp. is
an over-the-counter, specialty pharmaceutical company. Its flagship
product, PreHistin(TM) is currently in Phase III clinical trials
and initial marketing in the U.S. will commence upon final FDA
marketing approval. The U.S. anti-allergy medication market was
$7.2 billion in 2003 and is expected to exceed $10 billion by 2010.
PreHistin(TM), The World's First Pre-Histamine(TM), has shown in
previous studies to modulate the body's level of the protein IgE,
thereby reducing the overproduction of histamines, the primary
cause of airborne allergy symptoms. Prior studies have shown that
the active ingredient in PreHistin(TM) appears to have essentially
no risks of adverse effects to the general population, including
sedation and drowsiness found in many of the allergy products
currently available. For further information please visit the
website at http://www.cobalis.com/ SAFE HARBOR Certain statements
contained in this release are considered "forward-looking"
statements (as defined in the Private Securities Litigation Reform
Act of 1995). Because these statements include risks and
uncertainties, actual results may differ materially from those
expressed or implied. These forward-looking statements are
identified by their use of terms and phrases such as "believe,"
"expect," "plan," "anticipate," "possibility" and similar
expressions identifying their forward-looking character. Investors
should not rely on these forward-looking statements as assurances
of future events, because such statements are subject to a variety
of risks, uncertainties and other factors that could cause actual
results to differ materially from the Company's expectations.
Specifically, factors could include, but are not limited to: risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in the Company's
compounds under development in particular; the potential failure of
the Company's compounds under development to prove safe and
effective for treatment and prevention of disease; failure to
successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for the
Company's compounds under development; acquisitions, divestitures,
mergers, licenses or strategic initiatives that change the
Company's business, structure or projections; the development of
competing products; uncertainties related to the Company's
business, structure or projections; the development of competing
products; uncertainties related to the Company's dependence on
third parties and partners; and those risks described in filings
with the SEC. DATASOURCE: Cobalis Corp. CONTACT: Chas Radovich,
CEO, Cobalis Corp., +1-949-757-0001, ; Tim Clemensen, Senior Vice
President, Rubenstein Investor Relations, +1-212-843-9337, ;
Michelle Manoff, Senior Vice President, Rubenstein Public
Relations, +1-212- 843-8051, Web site: http://www.cobalis.com/
Copyright